Skip to main content
. Author manuscript; available in PMC: 2019 Apr 11.
Published in final edited form as: Cell Host Microbe. 2018 Mar 29;23(4):549–556.e3. doi: 10.1016/j.chom.2018.03.001

Figure 2. I.n. RVG9R-siFvEJW is therapeutic for WNV infection.

Figure 2.

(A) Kaplan-Meier survival curves of C3H mice treated with RVG9R-siRNA formulations at the indicated days p.i. with 100LD50 WNV. Data are from 3 experiments with mouse cohorts of atleast n = 5 mice per group per treatment. Survival statistics in all test cohorts (except treatment at days 6 & 7) achieved significance by the log-rank test when compared to mock- or siNT-treated mice. siNT = siLuc, siScr= scrambled siRNA for siFvEJW. (B) Mean WNV titers per gram of brain tissue at the indicated days p.i. Each data point represents one mouse. The dotted line depicts the assay’s limit of detection. ND- not detectable. (C) Representative images of mouse brain tissue sections analyzed by fluorescent immunohistochemistry at day 9 p.i. Scale bar = 30 µm. (D) Graphical presentation of data in (C) depicting MFI of GFAP-positive cells and numbers of TUNEL-positive cells per high power field (n=10) combined from 4 mice per treatment condition. See also Figure S3.